Amkas Labs

Amkas Labs is a biotechnology company focused on the discovery and development of small molecule therapeutics for rare genetic disorders caused by protein misfolding. The company utilizes a proprietary drug discovery platform to identify pharmacological chaperones that stabilize mutant proteins and restore their cellular function. Currently, Amkas Labs is advancing programs targeting Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency. The leadership team brings extensive experience from major pharmaceutical and biotech firms specializing in rare diseases. The company is headquartered in the San Francisco Bay Area and operates as a private entity. Its approach aims to provide disease-modifying treatments for patients with limited therapeutic options.